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ACEI

:   angiotensin‐converting enzyme inhibitors

Antihtn

:   antihypertensive medications

BB

:   beta blocker

CCB

:   calcium channel blocker

CHD

:   coronary heart disease

CVD

:   cardiovascular disease

Clinical PerspectiveWhat Is New?This systematic review with meta‐analysis shows that there are sex differences in cardiovascular medication prescription among patients at high risk or with established cardiovascular disease in primary care.Women were less likely to be prescribed aspirin, statin, or angiotensin‐converting enzyme inhibitor but more likely to have a prescription for diuretics.What Are the Clinical Implications?Sex differences in cardiovascular prescription in primary care need to be addressed in order to optimize the use of cardiovascular medication for both women and men.

 {#jah35070-sec-0008}

Cardiovascular disease (CVD) remains the leading cause of death worldwide, accounting for about a third of all deaths in both women and men.[1](#jah35070-bib-0001){ref-type="ref"} Historically, there has been a misperception that CVD predominantly affects men, which may have resulted in suboptimal management and treatment of CVD in women.[2](#jah35070-bib-0002){ref-type="ref"}, [3](#jah35070-bib-0003){ref-type="ref"} Over recent decades, substantial efforts have been made to characterize CVD in women. As a result, important differences between women and men in the presentation, diagnosis, and medical treatment of CVD have been identified.[2](#jah35070-bib-0002){ref-type="ref"}, [4](#jah35070-bib-0004){ref-type="ref"}

Most studies on sex differences in CVD management have been performed in secondary care.[3](#jah35070-bib-0003){ref-type="ref"}, [5](#jah35070-bib-0005){ref-type="ref"}, [6](#jah35070-bib-0006){ref-type="ref"}, [7](#jah35070-bib-0007){ref-type="ref"} For example, among all patients receiving statins after hospitalization for myocardial infarction in the United States, women were less likely than men to receive high‐intensity statins, despite guideline recommendations.[6](#jah35070-bib-0006){ref-type="ref"} Also, a study of coronary heart disease patients recruited from routine outpatient cardiology clinics in 11 countries across Europe, Asia, and the Middle East showed that women were less likely than men to reach all treatment targets set by clinical guidelines.[3](#jah35070-bib-0003){ref-type="ref"} Whether similar sex differences exist in primary care has not been systematically evaluated. Considering that both patients at high risk and with established CVD attended clinics in primary care to monitor their current CVD treatment, primary care visits are a key stage at which any sex inequities in treatment could and should be investigated. Comprehensive evidence on current sex differences in cardiovascular medication prescription in primary care would help to obtain a better understanding of the utilization of evidence‐based medical treatment for both sexes and encourage all health professionals to strive for sex equity in providing CVD management to their patients.

In this study, we conducted a systematic review and meta‐analysis to determine the prevalence of common cardiovascular medication prescription in women and men in primary care and to evaluate whether prescriptions for guideline‐recommended cardiovascular medications differ between the sexes.

Methods {#jah35070-sec-0009}
=======

The authors declare that all supporting data are available within the article and its online supplementary files.

Search Strategy {#jah35070-sec-0010}
---------------

A systematic search of observational studies was performed in PubMed/MEDLINE and Embase for studies published between 2000 and 2019 using combined text word subject heading terms (Table [S1](#jah35070-sup-0001){ref-type="supplementary-material"}). The reference lists of all related articles were screened for any other potentially relevant studies.

Study Selection and Data Extraction {#jah35070-sec-0011}
-----------------------------------

All observational studies that reported the sex‐specific prevalence of prescriptions of cardiovascular medications (aspirin, statins, and any antihypertensive medication including beta blockers, calcium channel blockers \[CCBs\], angiotensin‐converting enzyme inhibitors \[ACE inhibitors\], and diuretics) for patients at high risk or with established CVD (coronary heart disease, stroke, heart failure, and atrial fibrillation) in primary care were included. Studies were excluded if they (1) were published in a language other than English; (2) presented an unrelated study population, outcome, or were not performed in primary care; (3) included \<1000 patients; (4) reported cardiovascular medication prescription only for 1 sex; and (5) assessed cardiovascular medication not by prescription (such as self‐report or pharmacy dispensing).

Duplicate records were removed before title and abstract screening. When there were multiple reports from the same study, the report involving the highest number of cases or most explicit participants characteristics and outcome measures was included. Four independent reviewers (M.Z., E.R.C.M., C.C., and K.H.) screened the papers by title and abstract against the inclusion and exclusion criteria. Any disagreement between reviewers was discussed and the full text was reviewed, if necessary. A similar process took place in reviewing the full text of selected papers. A tailor‐made data extraction form was used to collect information on study and participant characteristics and sex‐specific prevalence of prescriptions of cardiovascular medication (Table [S2](#jah35070-sup-0001){ref-type="supplementary-material"}).

Quality Assessment {#jah35070-sec-0012}
------------------

Study quality was assessed using the modified Newcastle‐Ottawa scale for observational studies. This scale consists of 6 items that assess the quality of participant selection, comparability, and outcome adjudication (Tables [S3](#jah35070-sup-0001){ref-type="supplementary-material"} and [S4](#jah35070-sup-0001){ref-type="supplementary-material"}).[8](#jah35070-bib-0008){ref-type="ref"}

Outcomes {#jah35070-sec-0013}
--------

The primary outcome was the women‐to‐men prescription prevalence ratio with 95% CI for each cardiovascular medication. The secondary outcomes were the sex‐specific prescription rates of each cardiovascular medication.

Statistical Analysis {#jah35070-sec-0014}
--------------------

In general, the included studies reported unadjusted numbers, rates, or percentages of women and men with cardiovascular medication prescriptions. If a measure of variability was not reported, these were estimated from the rate and the sample size. The women‐to‐men prevalence ratios with 95% CI were pooled across studies using random‐effects meta‐analyses with inverse‐variance weighting for each medication.[9](#jah35070-bib-0009){ref-type="ref"} In sensitivity analysis, we pooled the results from studies that had adjusted for age. As different studies reported on different antihypertensive medications, we also restricted the analyses on individual antihypertensive medications to studies that reported on each of the 4 antihypertensive medications. Metaregression analyses were performed to assess the impact of mean age and age difference (women minus men) on our findings. We further investigated whether there was a trend in sex differences in cardiovascular medication prescription over time. In subgroup analysis, we assessed whether the findings differed by CVD status (high risk only, prevalent CVD, and high risk and prevalent CVD combined). *P*\<0.05 were considered statistically significant. Statistical analyses were performed by using the "metafor" package in R version 3.2.2.

Results {#jah35070-sec-0015}
=======

Study Characteristics {#jah35070-sec-0016}
---------------------

Of the 10 803 studies identified through the systematic search, 900 studies were reviewed in full text (Figure [1](#jah35070-fig-0001){ref-type="fig"}). Of these, 43 studies were included, including a total of 2 264 600 participants, of whom 630 111 (28%) were women. The mean age ranged from 51 to 76 years (where reported). [Table](#jah35070-tbl-0001){ref-type="table"} shows the key characteristics of the included studies. Of the 43 studies, 18 included information on aspirin,[10](#jah35070-bib-0010){ref-type="ref"}, [11](#jah35070-bib-0011){ref-type="ref"}, [12](#jah35070-bib-0012){ref-type="ref"}, [13](#jah35070-bib-0013){ref-type="ref"}, [14](#jah35070-bib-0014){ref-type="ref"}, [15](#jah35070-bib-0015){ref-type="ref"}, [16](#jah35070-bib-0016){ref-type="ref"}, [17](#jah35070-bib-0017){ref-type="ref"}, [18](#jah35070-bib-0018){ref-type="ref"}, [19](#jah35070-bib-0019){ref-type="ref"}, [20](#jah35070-bib-0020){ref-type="ref"}, [21](#jah35070-bib-0021){ref-type="ref"}, [22](#jah35070-bib-0022){ref-type="ref"}, [23](#jah35070-bib-0023){ref-type="ref"}, [24](#jah35070-bib-0024){ref-type="ref"}, [25](#jah35070-bib-0025){ref-type="ref"}, [26](#jah35070-bib-0026){ref-type="ref"}, [27](#jah35070-bib-0027){ref-type="ref"} 30 on statins,[^\*^](#jah35070-note-1003){ref-type="fn"} 14 on any antihypertensive medications,[^†^](#jah35070-note-1004){ref-type="fn"} 21 on beta blockers,[^‡^](#jah35070-note-1005){ref-type="fn"} 13 on CCBs,[^§^](#jah35070-note-1006){ref-type="fn"} 21 on ACE inhibitors,[^\|\|^](#jah35070-note-1007){ref-type="fn"} and 14 on diuretics.[^¶^](#jah35070-note-1008){ref-type="fn"} Eight out of 43 studies reported cardiovascular medication prescription for high‐risk patients,[17](#jah35070-bib-0017){ref-type="ref"}, [32](#jah35070-bib-0032){ref-type="ref"}, [38](#jah35070-bib-0038){ref-type="ref"}, [47](#jah35070-bib-0047){ref-type="ref"}, [48](#jah35070-bib-0048){ref-type="ref"}, [49](#jah35070-bib-0049){ref-type="ref"}, [52](#jah35070-bib-0052){ref-type="ref"}, [53](#jah35070-bib-0053){ref-type="ref"} 24 for patients with established CVD,[^\#^](#jah35070-note-1009){ref-type="fn"} and 11 for both high‐risk and CVD patients.[^\*\*^](#jah35070-note-1010){ref-type="fn"}

![Flowchart of records screened and included in the systematic review.\
ACEI indicates angiotensin‐converting enzyme inhibitor; and CCB, calcium channel blocker.](JAH3-9-e014742-g001){#jah35070-fig-0001}

###### 

Key Characteristics of Selected Studies

  Study                                                         Year                                          Country     Prevention Type   Sample Size   Women     Men       Age, y   Cardiovascular Medications                       
  ------------------------------------------------------------- --------------------------------------------- ----------- ----------------- ------------- --------- --------- -------- ---------------------------- --- --- --- --- --- ---
  Al‐Lawati et al[10](#jah35070-bib-0010){ref-type="ref"}       2007                                          Oman        Mixed             2551          1352      1199      54       X                                X   X   X   X   X
  Alberts et al[28](#jah35070-bib-0028){ref-type="ref"}         2004                                          Multiple    Secondary         55 499        18 315    37 184    69                                    X                   
  Brady et al[11](#jah35070-bib-0011){ref-type="ref"}           1998                                          UK          Secondary         24 431        9898      14 533    67       X                            X       X   X   X   X
  Brady et al[20](#jah35070-bib-0020){ref-type="ref"}           2002                                          UK          Secondary         12 045        4457      7588      67       X                            X       X       X   X
  Bull et al[31](#jah35070-bib-0031){ref-type="ref"}            2003[a](#jah35070-note-0004){ref-type="fn"}   UK          Secondary         13 929        5827      8102      \>40                                  X                   
  Carlsson et al[21](#jah35070-bib-0021){ref-type="ref"}        2013[a](#jah35070-note-0004){ref-type="fn"}   Sweden      Secondary         7408          3330      4078      76       X                            X       X   X       X
  Carroll et al[22](#jah35070-bib-0022){ref-type="ref"}         2001                                          UK          Secondary         6778          2787      3991      NA       X                            X       X           
  Catalán‐Ramos et al[32](#jah35070-bib-0032){ref-type="ref"}   2009                                          Spain       Primary           696 073       358 218   337 855   51                                    X       X   X   X   X
  Crilly et al[23](#jah35070-bib-0023){ref-type="ref"}          2001                                          UK          Secondary         1162          552       610       69       X                            X       X           
  Dodhia et al[33](#jah35070-bib-0033){ref-type="ref"}          2013                                          UK          Secondary         6711          2828      4564      70                                    X                   
  Dreyer et al[34](#jah35070-bib-0034){ref-type="ref"}          2007                                          Australia   Secondary         2005          721       1284      70                                    X       X   X   X   
  Driscoll et al[24](#jah35070-bib-0024){ref-type="ref"}        2007                                          Australia   Secondary         12 509        5267      7242      73       X                                X               
  Emberson et al[25](#jah35070-bib-0025){ref-type="ref"}        2001                                          UK          Mixed             8538          4286      4252      NA       X                            X   X   X       X   
  Forster et al[35](#jah35070-bib-0035){ref-type="ref"}         2013                                          UK          Secondary         23 811        4502      4252      NA                                    X   X               
  Greving et al[49](#jah35070-bib-0049){ref-type="ref"}         2000                                          NL          Primary           7550          4774      2776      63                                            X   X   X   X
  Gulliford et al[36](#jah35070-bib-0036){ref-type="ref"}       2010[a](#jah35070-note-0004){ref-type="fn"}   UK          Secondary         7065          3816      3249      73                                    X   X               
  Hawkins et al[50](#jah35070-bib-0050){ref-type="ref"}         2007                                          UK          Secondary         13 330        6803      6527      68                                            X       X   
  Hendrix et al[26](#jah35070-bib-0026){ref-type="ref"}         2005[a](#jah35070-note-0004){ref-type="fn"}   US          Mixed             72 508        29 208    43 300    NA       X                            X       X   X   X   X
  Hippisley‐Cox et al[27](#jah35070-bib-0027){ref-type="ref"}   2001[a](#jah35070-note-0004){ref-type="fn"}   UK          Mixed             5891          2783      3108      NA       X                                    X           
  Hyun et al[37](#jah35070-bib-0037){ref-type="ref"}            2012                                          Australia   Mixed             13 294        6202      7092      61                                    X   X               
  Journath et al[38](#jah35070-bib-0038){ref-type="ref"}        2005                                          Sweden      Primary           6537          3410      3127      66                                    X   X   X   X   X   X
  Lahoz et al[12](#jah35070-bib-0012){ref-type="ref"}           2008[a](#jah35070-note-0004){ref-type="fn"}   Spain       Secondary         8817          2319      6498      65       X                            X       X   X   X   X
  Law et al[44](#jah35070-bib-0044){ref-type="ref"}             2010                                          Canada      Primary           390           128       262       58                                    X                   
  Lawlor et al[29](#jah35070-bib-0029){ref-type="ref"}          2000                                          UK          Secondary         1314          483       831       NA                                    X                   
  Lee et al[19](#jah35070-bib-0019){ref-type="ref"}             2018                                          Australia   Secondary         130 926       61 142    69 784    67       X                            X   X   X       X   
  Macchia et al[13](#jah35070-bib-0013){ref-type="ref"}         2012[a](#jah35070-note-0004){ref-type="fn"}   Italy       Secondary         21 423        6928      14 495    NA       X                            X       X       X   
  Majeed et al[39](#jah35070-bib-0039){ref-type="ref"}          1996                                          UK          Secondary         63 259        34 545    28 714    NA                                    X                   
  Majeed et al[14](#jah35070-bib-0014){ref-type="ref"}          2002                                          UK          Secondary         2129          1224      905       NA       X                                            X   X
  Murphy et al[51](#jah35070-bib-0051){ref-type="ref"}          2004[a](#jah35070-note-0004){ref-type="fn"}   UK          Secondary         2186          1213      973       NA                                            X       X   X
  Nanna et al[46](#jah35070-bib-0046){ref-type="ref"}           2015                                          US          Mixed             5693          2460      3233      68                                    X                   
  Nilsson et al[40](#jah35070-bib-0040){ref-type="ref"}         2004[a](#jah35070-note-0004){ref-type="fn"}   Sweden      Mixed             9375          4293      5082      65                                    X               X   
  Nilsson et al[52](#jah35070-bib-0052){ref-type="ref"}         2007[a](#jah35070-note-0004){ref-type="fn"}   Sweden      Primary           1135          714       421       52                                                X   X   X
  Owen et al[47](#jah35070-bib-0047){ref-type="ref"}            2009[a](#jah35070-note-0004){ref-type="fn"}   Australia   Primary           12 499        5896      6603      63                                        X   X   X   X   X
  Paulsen et al[48](#jah35070-bib-0048){ref-type="ref"}         2011[a](#jah35070-note-0004){ref-type="fn"}   Denmark     Primary           5413          3305      2108      66                                        X   X   X   X   X
  Qato et al[15](#jah35070-bib-0015){ref-type="ref"}            2011                                          US          Mixed             4136          2233      1903      52       X                            X                   
  Saposnik et al[30](#jah35070-bib-0030){ref-type="ref"}        2004                                          Canada      Secondary         1094          415       679       67                                    X   X               
  Sheppard et al[41](#jah35070-bib-0041){ref-type="ref"}        2009                                          UK          Mixed             4699          1937      2762      54                                    X                   
  Svilaas et al[16](#jah35070-bib-0016){ref-type="ref"}         2000[a](#jah35070-note-0004){ref-type="fn"}   Norway      Secondary         2060          707       1353      69       X                                                
  Tabenkin et al[17](#jah35070-bib-0017){ref-type="ref"}        2004                                          US          Primary           407           210       197       53       X                                X           X   
  Turnbull et al[42](#jah35070-bib-0042){ref-type="ref"}        2008                                          Australia   Mixed             3664          1834      1830      68                                    X   X               
  Virani et al[43](#jah35070-bib-0043){ref-type="ref"}          2011                                          US          Secondary         972 532       13 371    959 161   71                                    X                   
  Weler et al[18](#jah35070-bib-0018){ref-type="ref"}           2003                                          US          Mixed             3849          1953      1896      65       X                                X               
  Wandell et al[45](#jah35070-bib-0045){ref-type="ref"}         2007                                          Sweden      Secondary         7975          3465      4510      NA                                    X       X   X   X   X

ACEI indicates angiotensin converting enzyme inhibitor; Antihtn, any anti‐hypertensive medication; BB, beta blocker; CCB, calcium channel blocker; EU, Europe; NL, The Netherlands; UK, United Kingdom; and US, United States.

Year: study performed year. Studies with asterisk indicate publication year.

John Wiley & Sons, Ltd

Sex Differences in Prevalence of Cardiovascular Medication Prescription {#jah35070-sec-0017}
-----------------------------------------------------------------------

In women, the pooled prevalence of cardiovascular medication prescription was 41% for aspirin, 60% for statins, and 68% for overall antihypertensive medications. The corresponding rates for men were 56%, 63%, and 69%, respectively. The pooled women‐to‐men prevalence ratios were 0.81 (95% CI, 0.72--0.92) for aspirin, 0.90 (95% CI, 0.85--0.95) for statins, and 1.01 (95% CI, 0.95--1.08) for any antihypertensive medications (Figure [2](#jah35070-fig-0002){ref-type="fig"}).

![Women‐to‐men prevalence ratio of aspirin, statins, and any antihypertensive medications prescription.\
For each study, the square is centered on the women‐to‐men prevalence ratio and the horizontal lines show the associated 95% CI. The diamond indicates the pooled summary and its 95% CI.](JAH3-9-e014742-g002){#jah35070-fig-0002}

Figure [3](#jah35070-fig-0003){ref-type="fig"} shows the women‐to‐men prevalence ratios of individual antihypertensive medication prescription. Women were less likely to be prescribed with ACE inhibitors (women‐to‐men prevalence ratio: 0.85; 95% CI, 0.81--0.89) whereas the prevalence of diuretics prescription was higher than in men (women‐to‐men prevalence ratio: 1.27; 95% CI, 1.17--1.37). There were no significant sex differences in the prescription of beta blockers and CCBs. Findings were similar in analyses restricted to studies that reported on all 4 individual antihypertensive medications (Figure [S1](#jah35070-sup-0001){ref-type="supplementary-material"}). Findings were similar in age‐adjusted analyses, available for 31 studies (Tables [S5](#jah35070-sup-0001){ref-type="supplementary-material"} through [S10](#jah35070-sup-0001){ref-type="supplementary-material"}).

![Women‐to‐men prevalence ratio of individual antihypertensive medication prescription.\
For each study, the square is centered on the women‐to‐men prevalence ratio and the horizontal lines show the associated 95% CI. The diamond indicates the pooled summary and its 95% CI.](JAH3-9-e014742-g003){#jah35070-fig-0003}

Impact of Age on the Sex Differences in Prevalence of Cardiovascular Medication {#jah35070-sec-0018}
-------------------------------------------------------------------------------

Among the 31 studies that reported a sex‐combined mean age of the study population, there was no evidence that the women‐to‐men prevalence ratio varied systematically according to the mean age (Figure [S2](#jah35070-sup-0001){ref-type="supplementary-material"}; *P* values: 0.57 for aspirin; 0.24 for beta blockers; 0.27 for CCBs; 0.41 for ACE inhibitors; 0.85 for diuretics). The only exception was that in studies with older patients, women were less likely than men to be prescribed statins whereas women had a higher prevalence of statin prescription compared with men in studies including younger patients (*P*=0.003).

Among the 17 studies that reported sex‐specific mean ages, there was no evidence that the prevalence ratio varied systematically according to the women to men age difference (Figure [S3](#jah35070-sup-0001){ref-type="supplementary-material"}; *P* values: 0.34 for aspirin; 0.21 for statins; 0.93 for beta blockers; 0.91 for CCBs; 0.89 for ACE inhibitors). The exception was the higher prevalence of diuretics prescription in women increased as the difference between the mean age of women and the mean age of men increased (*P*=0.006).

Sex Differences in the Prevalence of Cardiovascular Medication Prescription Over Time {#jah35070-sec-0019}
-------------------------------------------------------------------------------------

The sex differences in prevalence ratio of prescription did not significantly change over time for aspirin (*P*=0.92), any antihypertensive medications (*P*=0.99), beta blockers (*P*=0.43), CCBs (*P*=0.44), ACE inhibitors (*P*=0.39), and diuretics (*P*=0.58) (Figure [S4](#jah35070-sup-0001){ref-type="supplementary-material"}). However, the pattern and magnitude of the sex differences in statin prescription changed over time, with an increased women‐to‐men prevalence ratio (*P*=0.003).

Sex Differences in Cardiovascular Medication Prescription by CVD Status {#jah35070-sec-0020}
-----------------------------------------------------------------------

Among patients with established CVD, women were less likely to be prescribed with aspirin (0.89, 95% CI, 0.84--0.94), statins (0.85; 95% CI, 0.80--0.90), beta blockers (0.90, 95% CI, 0.85--0.96), and ACE inhibitors (0.88, 95% CI, 0.84--0.93) (Figure [S5](#jah35070-sup-0001){ref-type="supplementary-material"}, Table [S11](#jah35070-sup-0001){ref-type="supplementary-material"}). In contrast, women with established CVD were more likely to be prescribed with diuretics than their male counterparts (1.25; 95% CI, 1.09--1.43). Similar pooled estimates, but with wider CIs, were found when studies included only high‐risk participants, or when studies included both participants at high risk of and with established CVD. Time trends in the women‐to‐men prevalence ratio in medication prescription did not differ materially by CVD status (Figures [S6](#jah35070-sup-0001){ref-type="supplementary-material"} through [S11](#jah35070-sup-0001){ref-type="supplementary-material"}). However, the women‐to‐men ratio of statin prescription increased over time in studies among high‐risk patients but not in studies including patients with established CVD or in studies including both high‐risk and CVD patients (*P* for interaction=0.002).

Discussion {#jah35070-sec-0021}
==========

In this systematic review and meta‐analysis of 43 studies including over 2 million participants, we found that there were sex differences in cardiovascular medication prescription among patients at high risk or with established CVD in primary care. Compared with men, women were less likely to have a prescription for aspirin, statins, or ACE inhibitors but more likely to have a prescription for diuretics. Sex differences did not vary materially by age, but there was some evidence to suggest that the magnitude of sex differences in statin prescription increased over time.

Previous studies in secondary care have demonstrated that women are generally less likely than men to have a prescription of guideline‐recommended cardiovascular medications after a cardiac event.[2](#jah35070-bib-0002){ref-type="ref"}, [3](#jah35070-bib-0003){ref-type="ref"}, [5](#jah35070-bib-0005){ref-type="ref"}, [54](#jah35070-bib-0054){ref-type="ref"} SUrvey of Risk Factors, a clinical audit with over 10 000 patients from 11 countries, indicated that women had a lower prevalence of cardiovascular medication use than men and were less likely to reach treatment targets.[3](#jah35070-bib-0003){ref-type="ref"} Similarly, a study of 36 000 patients with established coronary heart disease in the United States, showed that women were less likely than men to be prescribed with aspirin, ACE inhibitors, or statins at both acute and hospital discharge of coronary heart disease.[55](#jah35070-bib-0055){ref-type="ref"} A study in the United Kingdom showed that prescription rates for cardiovascular medications were about 10% lower among women than men \<55 years for acute myocardial infarction.[56](#jah35070-bib-0056){ref-type="ref"} Furthermore, a Dutch population‐based analysis also found persistent sex differences in the use of lipid‐lowering medications for secondary prevention of CVD, particularly in younger patients.[5](#jah35070-bib-0005){ref-type="ref"} We did not observe that sex disparities differed between age groups, but we noticed that the sex differences in statin prescription persisted and was even larger in the more recent studies. A recent study in the United States confirmed that women were 9% less likely than men to receive high‐intensity statins, as opposed to other types of statin.[57](#jah35070-bib-0057){ref-type="ref"} The present study further expands these findings by showing that sex differences in medication prescription also exist among patients at high cardiovascular risk or with established CVD in a primary care setting. We also demonstrated that women were more likely to be on diuretics but less likely to be on ACE inhibitors, which is in line with other studies.[56](#jah35070-bib-0056){ref-type="ref"}, [58](#jah35070-bib-0058){ref-type="ref"}, [59](#jah35070-bib-0059){ref-type="ref"} Sex differences in progression and presentation of CVD and comorbidities, the efficiency of treatment, and/or adverse drug effects may lead to different requirements on antihypertensive regimens.[59](#jah35070-bib-0059){ref-type="ref"}, [60](#jah35070-bib-0060){ref-type="ref"} The reasons for the contrasting sex differences within antihypertensive medication classes require further study.

There are several other possible explanations for the lower prescription rates of some cardiovascular medications in women than men. First, the incidence of CVD in women is, typically, about a third that of men in middle age and occurs in men about a decade earlier than women, which might have led to the misperception that CVD is less common in women and does not have to be prevented as intensively as in men.[4](#jah35070-bib-0004){ref-type="ref"}, [34](#jah35070-bib-0034){ref-type="ref"}, [61](#jah35070-bib-0061){ref-type="ref"} Additionally, women may have a lower awareness of the severity of their disease and of appropriate CVD treatment and receive less support from healthy providers, compared with men, resulting in lower health consciousness and less frequent use of healthcare services.[5](#jah35070-bib-0005){ref-type="ref"}, [62](#jah35070-bib-0062){ref-type="ref"}, [63](#jah35070-bib-0063){ref-type="ref"}, [64](#jah35070-bib-0064){ref-type="ref"}

Although beyond the scope of the current investigation, studies have reported a considerable delay in receiving appropriate medical treatment to reduce the risk of incident or recurrent cardiac event in women.[2](#jah35070-bib-0002){ref-type="ref"}, [23](#jah35070-bib-0023){ref-type="ref"}, [62](#jah35070-bib-0062){ref-type="ref"}, [63](#jah35070-bib-0063){ref-type="ref"} Also, women may have less belief than men in the safety and effectiveness of cardiovascular medications and have been reported to have a greater risk of suffering adverse drug reactions, which may lead to a higher discontinuation rate of cardiovascular medications.[60](#jah35070-bib-0060){ref-type="ref"}, [65](#jah35070-bib-0065){ref-type="ref"}, [66](#jah35070-bib-0066){ref-type="ref"}, [67](#jah35070-bib-0067){ref-type="ref"} Indeed, studies have shown that women have a poorer adherence to cardiovascular medication than men in primary care.[68](#jah35070-bib-0068){ref-type="ref"}, [69](#jah35070-bib-0069){ref-type="ref"} These factors would be expected to produce a wider disparity between the usage of cardiovascular medications than our study of prescriptions suggests.

We conducted a large‐scale systematic review with meta‐analyses on sex differences in cardiovascular medication prescription among patients at high risk or with established CVD in a primary care setting. We included all major cardiovascular medications and found that our results were generally robust across patient characteristics. Limitations of this study are inherent to its design and include the differences across studies in design, population, and end point definition.[9](#jah35070-bib-0009){ref-type="ref"} We had no information on potential combinations of cardiovascular medications prescribed, nor were we able to adjust our findings to potentially important comorbidities or other characteristics. However, some cardiovascular medications target the same risk factor and the lower use of ACE inhibitors among women, relative to men, could be explained by women\'s higher use of diuretics. Also, we considered sex differences only in medication prescription and were not able to determine whether those differences, where found, resulted in different levels of risk factor control and event rates. Furthermore, patients with established CVD seen in primary care may also receive treatment from secondary care. Also, it is not clear whether general practitioners or cardiologists would be the main source of prescriptions in any individual case. Finally, as the studies included in this review were conducted in mostly high‐income countries, the generalizability of our findings to low‐ and middle‐income countries needs to be assessed.

In conclusion, this meta‐analysis, summarizing all recent literature, shows that sex differences in cardiovascular medication prescription persist in primary care. Future research is needed to determine the underlying causes of observed sex differences and to develop tailored strategies to optimize the use of evidence‐based cardiovascular medication for both women and men.
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